Topical Therapy for Atopic Dermatitis: New and Investigational Agents
Recommended Citation
Stein Gold LF, Eichenfield LF. Topical Therapy for Atopic Dermatitis: New and Investigational Agents. Seminars in cutaneous medicine and surgery 2017; 36(4S):S99-S102.
Document Type
Article
Publication Date
12-1-2017
Publication Title
Seminars in cutaneous medicine and surgery
Abstract
Recently a new class of topical medications for mild to moderate atopic dermatitis has been introduced with US Food and Drug Administration (FDA) approval of the first new prescription medication for this condition in more than a decade. Crisaborole, the newly approved medication, has relieved pruritus in more than one-third of patients within as little as 48 hours. It also has demonstrated efficacy in patients with skin of color. Topical therapies representing other new approaches to atopic dermatitis, with novel mechanisms of action, have shown promise in clinical development. Semin Cutan Med Surg 36(supp4):S99-S102.
PubMed ID
29659644
Volume
36
Issue
4S
First Page
S99
Last Page
S102